Quality of Life Assessment in Surgical Oncology Trials

被引:0
作者
Kerry Avery
Jane M. Blazeby
机构
[1] University of Bristol,Department of Social Medicine
[2] University of Bristol,Department of Clinical Sciences at South Bristol
[3] Clinical Sciences at South Bristol,Surgery, Level 7
[4] Bristol Royal Infirmary,undefined
来源
World Journal of Surgery | 2006年 / 30卷
关键词
Minimal Important Difference; HRQL Measure; HRQL Instrument; Inform Treatment Decision; Instrument Selection;
D O I
暂无
中图分类号
学科分类号
摘要
Integrating health-related quality of life (HRQOL) as an endpoint for randomized surgical trials provides valuable insight into the patients’ perspective on treatment outcome. Health related quality of life data also play a role in ensuring fully informed consent, determining treatment options and informing treatment decision making. However, few randomized surgical trials have been conducted that meet the minimum requirements for rigorous HRQL assessment and, despite increasing efforts to improve the reporting of randomized trials, many are still not adequately performed. Such methodologic limitations may influence trial findings for HRQL outcomes and undermine the ability of the data collected to inform clinical practice. This review describes key methodological aspects of HRQL assessment that are required in randomized trials to ensure that data are robust. This includes choice of HRQL instrument, the method and timing of assessments and data analysis and presentation. The review also makes recommendations for future research in this area.
引用
收藏
页码:1163 / 1172
页数:9
相关论文
共 127 条
  • [1] Moher D(2001)The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials JAMA 285 1987-1991
  • [2] Schulz KF(1995)Evaluating new surgical procedures Br Med J 311 1243-1244
  • [3] Altman DG(2002)Quality improvement report: improving design and conduct of randomized trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult BMJ 325 766-770
  • [4] Russell I(1998)Understanding controlled trials. Randomising groups of patients Br Med J 316 1898-1900
  • [5] Donovan J(1996)Outcomes of cancer treatment for technology assessment and cancer treatment guidelines J Clin Oncol 14 671-679
  • [6] Mills N(2005)Ethics of palliative surgery in patients with cancer Br J Surg 92 802-809
  • [7] Smith M(2003)Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21 3502-3511
  • [8] Roberts C(2003)Health-related quality-of-life measurement in randomized clinical trials in breast cancer—taking stock J Natl Cancer Inst 95 263-197
  • [9] Sibbald B(2004)Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials Eur J Cancer 40 187-2992
  • [10] Hofmann B(2003)Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials J Clin Oncol 21 2982-125